Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

J. Faris · SciRah

Researcher profile · Semantic Scholar

J. Faris

Share profile

J. Faris — researcher profile on SciRah

h-index: 27
Works: 76
Citations: 6,576

Most-cited papers

Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations
D. Hyman, I. Puzanov, V. Subbiah, J. Faris +19 more
2015New England Journal of Medicine1,645 citations Open access
Semantic Scholar
A patient-level meta-analysis of FOLFIRINOX for locally advanced pancreatic cancer
M. Suker, Berend R. Beumer, E. Sadot, L. Marthey +16 more
2016The Lancet Oncology795 citations Open access
Semantic Scholar
Total Neoadjuvant Therapy With FOLFIRINOX Followed by Individualized Chemoradiotherapy for Borderline Resectable Pancreatic Adenocarcinoma: A Phase 2 Clinical Trial
J. Murphy, J. Wo, D. Ryan, Wen-Qing Jiang +14 more
2018JAMA Oncology516 citations Open access
Semantic Scholar
Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancer: A Phase 2 Clinical Trial.
J. Murphy, J. Wo, D. Ryan, J. Clark +27 more
2019JAMA Oncology476 citations Open access
Semantic Scholar
Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers
A. Parikh, I. Leshchiner, Liudmila Elagina, L. Goyal +43 more
2019Nature Medicine455 citations Open access
Semantic Scholar
Clinical acquired resistance to RAF inhibitor combinations in BRAF-mutant colorectal cancer through MAPK pathway alterations
Leanne G. Ahronian, E. Sennott, E. V. Van Allen, N. Wagle +21 more
2015Cancer Discovery305 citations Open access
Semantic Scholar
FOLFIRINOX in locally advanced pancreatic cancer: the Massachusetts General Hospital Cancer Center experience.
J. Faris, L. Blaszkowsky, S. McDermott, A. Guimaraes +17 more
2013The Oncologist281 citations Open access
Semantic Scholar
PD-1 Blockade in Anaplastic Thyroid Carcinoma
J. Capdevila, L. Wirth, T. Ernst, S. Aix +20 more
2020Journal of Clinical Oncology270 citations Open access
Semantic Scholar
A Phase 1b Dose-Escalation Study of Encorafenib (LGX818) and Cetuximab With or Without Alpelisib in Metastatic BRAF-Mutant Colorectal Cancer
R. van Geel, J. Tabernero, E. Élez, J. Bendell +19 more
2017Cancer Discovery202 citations Open access
Semantic Scholar
Radiological and Surgical Implications of Neoadjuvant Treatment With FOLFIRINOX for Locally Advanced and Borderline Resectable Pancreatic Cancer
C. Ferrone, G. Marchegiani, Theodore S. Hong, D. P. Ryan +17 more
2015Annals of Surgery128 citations Open access
Semantic Scholar
Prognosis and Clinicopathologic Features of Patients With Advanced Stage Isocitrate Dehydrogenase (IDH) Mutant and IDH Wild-Type Intrahepatic Cholangiocarcinoma.
L. Goyal, A. Govindan, R. Sheth, V. Nardi +19 more
2015The Oncologist127 citations Open access
Semantic Scholar
Circulating oncometabolite 2-hydroxyglutarate is a potential surrogate biomarker in patients with isocitrate dehydrogenase-mutant intrahepatic cholangiocarcinoma
D. Borger, L. Goyal, T. Yau, R. Poon +26 more
2014Clinical Cancer Research126 citations Open access
Semantic Scholar
Phase 2 results: Encorafenib (ENCO) and cetuximab (CETUX) with or without alpelisib (ALP) in patients with advanced BRAF-mutant colorectal cancer (BRAFm CRC).
J. Tabernero, R. van Geel, T. Guren, R. Yaeger +16 more
201696 citations
Semantic Scholar
Metabolic Consequences of Androgen Deprivation Therapy for Prostate Cancer
J. Faris, M. Smith
2010Current Opinion in Endocrinology, Diabetes & Obesity93 citations Open access
Semantic Scholar
Phase II trial of cabozantinib in patients with carcinoid and pancreatic neuroendocrine tumors (pNET).
J. Chan, J. Faris, J. Murphy, L. Blaszkowsky +13 more
201791 citations
Semantic Scholar
Plasmid DNA vaccines: assay for integration into host genomic DNA.
B. Ledwith, Sujata V. Manam, P. Troilo, A. Barnum +10 more
2000Developments in Biologicals87 citations
Semantic Scholar
A first-in-human phase 1 dose escalation study of spartalizumab (PDR001), an anti–PD-1 antibody, in patients with advanced solid tumors
A. Naing, J. Gainor, H. Gelderblom, P. Forde +14 more
2020Journal for ImmunoTherapy of Cancer81 citations Open access
Semantic Scholar
Mutational Analysis and Clinical Correlation of Metastatic Colorectal Cancer
A. Russo, D. Borger, J. Szymonifka, D. P. Ryan +13 more
2014Cancer77 citations Open access
Semantic Scholar
Convergent therapeutic strategies to overcome the heterogeneity of acquired resistance in BRAFV600E colorectal cancer
M. Hazar-Rethinam, M. Kleyman, G. Han, David Liu +19 more
2018Cancer Discovery68 citations Open access
Semantic Scholar
Phase II study of gemcitabine, oxaliplatin in combination with panitumumab in KRAS wild-type unresectable or metastatic biliary tract and gallbladder cancer
A. Hezel, Marcus S Noel, J. Allen, T. Abrams +21 more
2014British Journal of Cancer60 citations Open access
Semantic Scholar
Sunitinib (Sutent)-Induced Thyrotoxicosis Due to Destructive Thyroiditis: A Case Report
J. Faris, Allan F. Moore, G. Daniels
2007Thyroid53 citations
Semantic Scholar
Discovery and Optimization of HKT288, a Cadherin-6-Targeting ADC for the Treatment of Ovarian and Renal Cancers.
C. U. Bialucha, S. Collins, Xiao Li, Parmita Saxena +41 more
2017Cancer Discovery51 citations
Semantic Scholar
Phase I study of the selective BRAFV600inhibitor encorafenib (LGX818) combined with cetuximab and with or without the {alpha}-specific PI3K inhibitor BYL719 in patients with advanced BRAF-mutant colorectal cancer.
R. van Geel, E. Élez, J. Bendell, J. Faris +16 more
201451 citations
Semantic Scholar
Phase I Study of the Investigational Anti-Guanylyl Cyclase Antibody–Drug Conjugate TAK-264 (MLN0264) in Adult Patients with Advanced Gastrointestinal Malignancies
K. Almhanna, T. Kalebic, C. Cruz, J. Faris +6 more
2016Clinical Cancer Research42 citations Open access
Semantic Scholar
Phase I/II study of spartalizumab (PDR001), an anti-PD1 mAb, in patients with anaplastic thyroid cancer.
L. Wirth, E. Eigendorff, J. Capdevila, L. Paz-Ares +15 more
201841 citations
Semantic Scholar
Abstract PL04-05: The first reported results of AG-120, a first-in-class, potent inhibitor of the IDH1 mutant protein, in a Phase I study of patients with advanced IDH1-mutant solid tumors, including gliomas
H. Burris, I. Mellinghoff, E. Maher, P. Wen +11 more
201541 citations
Semantic Scholar
A phase II study of antibody-drug conjugate, TAK-264 (MLN0264) in previously treated patients with advanced or metastatic pancreatic adenocarcinoma expressing guanylyl cyclase C
K. Almhanna, D. Wright, T. M. Mercade, J. Van Laethem +16 more
2017Investigational new drugs33 citations
Semantic Scholar
Abstract LB319: IAG933, a selective and orally efficacious YAP1/WWTR1(TAZ)-panTEAD protein-protein interaction inhibitor with pre-clinical activity in monotherapy and combinations
T. Schmelzle, Emilie A. Chapeau, D. Bauer, P. Chène +19 more
2023Cancer Research24 citations
Semantic Scholar
A Phase 1 Study of a CDH6-Targeting Antibody-Drug Conjugate in Patients with Advanced Solid Tumors with Evaluation of Inflammatory and Neurological Adverse Events
P. Schöffski, N. Concin, C. Suárez, V. Subbiah +10 more
2021Oncology Research and Treatment24 citations
Semantic Scholar
TGF-B1 inhibition with losartan in combination with FOLFIRINOX (F-NOX) in locally advanced pancreatic cancer (LAPC): Preliminary feasibility and R0 resection rates from a prospective phase II study.
J. Murphy, J. Wo, C. Ferrone, Wen-Qing Jiang +15 more
201720 citations
Semantic Scholar
Tolerability and Long-term Outcomes of Dose-Painted Neoadjuvant Chemoradiation to Regions of Vessel Involvement in Borderline or Locally Advanced Pancreatic Cancer
J. Wo, A. Niemierko, D. Ryan, L. Blaszkowsky +12 more
2018American Journal of Clinical Oncology16 citations
Semantic Scholar
Phase I/II study of spartalizumab (PDR001), an anti-PD1 mAb, in patients with advanced melanoma or non-small cell lung cancer.
C.-C. Lin, M. Taylor, V. Boni, P. Brunsvig +16 more
2018Annals of Oncology14 citations Open access
Semantic Scholar
LBA-08Results of a phase 1b study of the selective BRAF V600 inhibitor encorafenib in combination with cetuximab alone or cetuximab + alpelisib for treatment of patients with advanced BRAF-mutant metastatic colorectal cancer
E. Élez, J. Schellens, R. van Geel, J. Bendell +17 more
201514 citations Open access
Semantic Scholar
Controversy and Consensus on the Management of Patients With Pseudomyxoma Peritonei
J. Faris, D. Ryan
2013Current Treatment Options in Oncology14 citations
Semantic Scholar
Targeted therapy for biliary tract cancers
J. Faris, A. Zhu
2012Journal of hepato-biliary-pancreatic sciences14 citations Open access
Semantic Scholar
Vemurafenib (VEM) in Relapsed Refractory Multiple Myeloma Harboring BRAF V600 Mutations (V600m): A Cohort of the Histology-Independent VE-Basket Study
N. Raje, I. Chau, D. Hyman, V. Ribrag +15 more
201513 citations
Semantic Scholar
11LBA Phase I study of the selective BRAFV600 inhibitor encorafenib (LGX818) combined with cetuximab and with or without the α-specific PI3K inhibitor alpelisib (BYL719) in patients with advanced BRAF mutant colorectal cancer
J. Tabernero, R. van Geel, J. Bendell, A. Spreafico +16 more
201411 citations
Semantic Scholar
392 Phase 1 study of CI-8993 anti-VISTA antibody in patients with advanced solid tumor malignancies
E. Martinez, J. Faris, R. V. von Roemeling, S. Angelides +1 more
202010 citations Open access
Semantic Scholar
Author Correction: Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers
A. Parikh, I. Leshchiner, Liudmila Elagina, L. Goyal +43 more
2019Nature Medicine10 citations
Semantic Scholar
FOLFIRINOX in locally advanced or metastatic pancreatic cancer.
J. Faris, T. Hong, S. McDermott, A. Guimaraes +4 more
2012Journal of Clinical Oncology10 citations
Semantic Scholar
MLN0264, an investigational antiguanylyl cyclase C (GCC) antibody-drug conjugate (ADC), in patients (pts) with advanced gastrointestinal (GI) malignancies: Phase I study.
C. Zambrano, K. Almhanna, W. Messersmith, J. Ahnert +6 more
20149 citations
Semantic Scholar
Abstract CT136: Final biomarker analysis of the phase I study of the selective BRAF V600 inhibitor encorafenib (LGX818) combined with cetuximab with or without the α-specific PI3K inhibitor alpelisib (BYL719) in patients with advanced BRAF-mutant colorectal cancer
J. Schellens, R. van Geel, J. Bendell, A. Spreafico +16 more
20158 citations
Semantic Scholar
A patient-level meta-analysis of FOLFIRINOX for locally advanced pancreatic cancer
M. Suker, E. Sadot, L. Marthey, S. Moorcraft +7 more
20167 citations Open access
Semantic Scholar
A Phase 2 Study of Oral MKC-1 in Patients with Unresectable or Metastatic Pancreatic Cancer
J. Faris, J. Arnott, Hui Zheng, D. Ryan +8 more
2011Investigational new drugs7 citations Open access
Semantic Scholar
Phase II study of autophagy inhibition with hydroxychloroquine (HCQ) and preoperative (preop) short course chemoradiation (SCRT) followed by early surgery for resectable ductal adenocarcinoma of the head of pancreas (PDAC).
T. Hong, J. Wo, Wen-Qing Jiang, B. Yeap +16 more
20176 citations
Semantic Scholar
A patient-level meta-analysis of FOLFIRINOX for locally advanced pancreatic cancer.
M. Suker, Berend R. Beumer, E. Sadot, L. Marthey +16 more
20166 citations Open access
Semantic Scholar
Dose intensity of neoadjuvant FOLFIRINOX (FFX) in borderline and locally advanced pancreatic cancer (LAPC): A comparison to the adjuvant benchmark.
J. Murphy, L. Ly, J. Wo, D. Ryan +16 more
2019Journal of Clinical Oncology5 citations
Semantic Scholar
Vemurafenib in Patients with Erdheim-Chester Disease (ECD) and Langerhans Cell Histiocytosis (LCH) Harboring BRAFV600 Mutations: A Cohort of the Histology-Independent VE-Basket Study
E. Diamond, V. Subbiah, Craig A. Lockhart, J. Blay +16 more
20165 citations Open access
Semantic Scholar
O-026Combination of encorafenib and cetuximab with or without alpelisib in patients with advanced BRAF-mutant colorectal cancer (BRAFm CRC): phase 2 results
J. Tabernero, R. van Geel, T. Guren, R. Yaeger +16 more
20165 citations Open access
Semantic Scholar
Targeted therapies: Sunitinib versus interferon-α in metastatic RCC
J. Faris, M. Michaelson
2010Nature Reviews Clinical Oncology5 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

J. Murphy×16
Invite
J. Murphy — researcher profile on SciRah
D. Ryan×16
Invite
D. Ryan — researcher profile on SciRah
L. Blaszkowsky×15
Invite
L. Blaszkowsky — researcher profile on SciRah
E. Kwak×15
Invite
E. Kwak — researcher profile on SciRah

×14

Invite

J. Allen — researcher profile on SciRah

Invite

T. Hong — researcher profile on SciRah

Invite

L. Goyal — researcher profile on SciRah

Invite

J. Wo — researcher profile on SciRah

Invite

A. Zhu — researcher profile on SciRah

Invite

J. Clark — researcher profile on SciRah

Invite

C. Ferrone — researcher profile on SciRah

Invite

M. Schuler — researcher profile on SciRah